Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Short term Debt: 2009-2015

Historic Short term Debt for Gyre Therapeutics (GYRE) over the last 6 years, with Dec 2015 value amounting to $1.2 million.

  • Gyre Therapeutics' Short term Debt fell 95.86% to $28,000 in Q3 2016 from the same period last year, while for Sep 2016 it was $28,000, marking a year-over-year decrease of 95.86%. This contributed to the annual value of $1.2 million for FY2015, which is N/A change from last year.
  • According to the latest figures from FY2015, Gyre Therapeutics' Short term Debt is $1.2 million, which was up 35.52% from $853,000 recorded in FY2013.
  • Gyre Therapeutics' Short term Debt's 5-year high stood at $1.2 million during FY2011, with a 5-year trough of $851,000 in FY2012.
  • Its 2-year average for Short term Debt is $1.0 million, with a median of $1.0 million in 2013.
  • In the last 5 years, Gyre Therapeutics' Short term Debt crashed by 31.43% in 2012 and then rose by 0.24% in 2013.
  • Over the past 4 years, Gyre Therapeutics' Short term Debt (Yearly) stood at $1.2 million in 2011, then plummeted by 31.43% to $851,000 in 2012, then rose by 0.24% to $853,000 in 2013, then reached $1.2 million in 2015.